PTC Therapeutics kicked off the week with a double-digit rally, driven by a Q1 earnings beat that cleared the bar by $0.42 EPS and pulled analysts back into the upgrade camp — a sharp reversal from the bearish drift that had defined the stock for much of the spring.
The catalyst was unmistakable. Q1 results dropped on May 7, and the stock logged a 10.7% one-day move before adding further ground Friday to close at $73.69 — up 13% on the week. The earnings beat was broad enough to reset expectations, with the print topping revenue estimates as well as EPS. TD Cowen moved the fastest, upgrading to Buy and lifting its target to $90 within 24 hours of the release. Wells Fargo followed with a raise to $95, holding its Overweight rating. Even RBC, which stayed at Sector Perform, nudged its target up to $82. The Street's mean target now sits at $89, implying roughly 21% upside from current levels — notable given that the stock was being trimmed by several of the same desks just weeks prior.
The short-interest setup added some mechanical fuel to the move. Shorts hold 10.4% of free float — a non-trivial position — and that cohort has been trimming steadily since mid-April, when shares outstanding short peaked near 9.65 million. By May 7, that figure had pulled back to around 8.38 million, a roughly 13% reduction from the April high. The borrow market is relaxed, with cost to borrow running near 0.43% — down more than 60% over the past month — and availability loose enough that there is no squeeze dynamic at work here. The week's rally reflects genuine sentiment improvement, not a mechanical short cover.
Options confirm the bullish tilt. The put/call ratio dropped to 0.27 on Friday, its lowest reading in months and below the 20-day average of 0.31. Call volume dominated as traders chased the move higher. The ratio is near the 52-week low of 0.21, so there is little protective hedging underway — the options market is leaning decisively into the upside rather than defending against a reversal.
Analyst skepticism has not vanished entirely. Jefferies downgraded to Hold in late March after cutting its target from $91 to $76, and the bear case centres on continued pressure from Translarna — whose European marketing authorisation was withdrawn — and execution risk around the Sephience PKU launch. Bulls counter that Sephience targets a roughly $1.2 billion market and offers meaningfully better patient compliance than existing treatments, and that the company's neuro pipeline provides optionality beyond the commercial base. At an EV/EBITDA of around 23x and a price-to-book near 25.7x (both down materially over 30 days as the price lagged until this week), the valuation had compressed enough to attract fresh buyers when the fundamental data improved.
Insider activity adds a mild caution note to the otherwise constructive picture. The CTO sold roughly $3.6 million worth of stock in early April, and the COO and Chief Legal Officer made smaller sales in the same window. Net insider activity across 90 days remains a modest positive in value terms — partly a function of the denominator — but the directional pattern of C-suite sales heading into earnings is worth registering. Institutional holders have been more positive: BlackRock added more than 5.6 million shares in its most recent filing, pushing its stake to 15.4% of shares outstanding, while State Street and Janus Henderson both reported material additions.
The next scheduled catalyst is a June 2 earnings call. Between now and then, the conversation will turn on whether Sephience uptake data supports the bullish launch thesis, or whether the bears' concerns about below-guidance commercial revenues prove prescient after a quarter that beat largely on non-recurring dynamics.
See the live data behind this article on ORTEX.
Open PTCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
